EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Matching study design to prescribing intention: The prevalent new‐user design for studying abuse‐deterrent formulations of opioids

Bethany L DiPrete iD, GYeon Oh iD, Daniela C Moga iD, Nabarun Dasgupta iD, Svetla Slavova iD, Emily Slade, Chris Delcher iD, Brian W Pence, Shabbar I Ranapurwala iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Bethany L DiPrete und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Opioid-Related Disorders, Practice Patterns, Physicians', Abuse-Deterrent Formulations. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCIPC CDC HHS, NIDA NIH HHS, US Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In drug studies, research designs requiring no prior exposure to certain drug classes may restrict important populations. Since abuse‐deterrent formulations (ADF) of opioids are routinely prescribed after other opioids, choice of study design, identification of appropriate comparators, and addressing confounding by “indication” are important considerations in ADF post‐marketing studies.

Methods

In a retrospective cohort study using claims data (2006–2018) from a North Carolina private insurer [NC claims] and Merative MarketScan [MarketScan], we identified patients (18–64 years old) initiating ADF or non‐ADF extended‐release/long‐acting (ER/LA) opioids. We compared patient characteristics and described opioid treatment history between treatment groups, classifying patients as traditional (no opioid claims during prior six‐month washout period) or prevalent new users.

Results

We identified 8415 (NC claims) and 147 978 (MarketScan) ADF, and 10 114 (NC claims) and 232 028 (MarketScan) non‐ADF ER/LA opioid initiators. Most had prior opioid exposure (ranging 64%–74%), and key clinical differences included higher prevalence of recent acute or chronic pain and surgery among patients initiating ADFs compared to non‐ADF ER/LA initiators. Concurrent immediate‐release opioid prescriptions at initiation were more common in prevalent new users than traditional new users.

Conclusions

Careful consideration of the study design, comparator choice, and confounding by “indication” is crucial when examining ADF opioid use‐related outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidOpioid-Related DisordersPractice Patterns, Physicians'Abuse-Deterrent FormulationsResearch DesignHumansRetrospective StudiesMiddle AgedMaleFemaleAdultYoung AdultAdolescentNorth CarolinaDelayed-Action PreparationsCohort StudiesDrug Prescriptions

Stichwörter der Autor:innen

opioid analgesicsopioid prescribingopioid related disorderpostmarketing evaluation studiesstudy design

Substanzen

Analgesics, OpioidAbuse-Deterrent FormulationsDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Injury Prevention Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
  • Institute for Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
  • Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.
  • Department of Epidemiology and Environmental Health, University of Kentucky, Lexington, Kentucky, USA.

ORCID-Profile: Bethany L DiPrete, GYeon Oh, Daniela C Moga, Nabarun Dasgupta, Svetla Slavova, Chris Delcher, Shabbar I Ranapurwala

Förderung

  • NCIPC CDC HHS
  • NIDA NIH HHS
  • US Food and Drug Administration

Zitieren

APA

DiPrete, B. L., Oh, G., Moga, D. C., Dasgupta, N., Slavova, S., Slade, E., Delcher, C., Pence, B. W., & Ranapurwala, S. I. (2024). Matching study design to prescribing intention: The prevalent new‐user design for studying abuse‐deterrent formulations of opioids. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5805

Vancouver

DiPrete BL, Oh G, Moga DC, Dasgupta N, Slavova S, Slade E, et al. Matching study design to prescribing intention: The prevalent new‐user design for studying abuse‐deterrent formulations of opioids. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5805

BibTeX
@article{DiPrete2024,
  author = {DiPrete, Bethany L and Oh, GYeon and Moga, Daniela C and Dasgupta, Nabarun and Slavova, Svetla and Slade, Emily and Delcher, Chris and Pence, Brian W and Ranapurwala, Shabbar I},
  title = {Matching study design to prescribing intention: The prevalent new‐user design for studying abuse‐deterrent formulations of opioids},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5805}
}
Kostenlos starten →